Musculoskeletal Disorders Drugs Global Market Report 2022 – Yahoo Finance

Major companies in the musculoskeletal disorders drugs market include Sanofi S. A, Pfizer Inc. , Bristol-Myers Squibb, Eli Lilly And Company, Mitsubishi Tanabe Pharma Corporation, Horizon Therapeutics plc.
New York, March 04, 2022 (GLOBE NEWSWIRE) — announces the release of the report "Musculoskeletal Disorders Drugs Global Market Report 2022" –
, Procter & Gamble, Eisai Co. Ltd., Biogen Inc. and Sino Biopharmaceutical.

The global musculoskeletal disorders drugs market is expected to grow from $97.45 billion in 2021 to $104.03 billion in 2022 at a compound annual growth rate (CAGR) of 6.8%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $126.34 billion in 2026 at a CAGR of 5.0%.

The musculoskeletal disorders drugs market consists of sales of musculoskeletal disorders drugs and related services by entities (organizations, sole traders and partnerships) that produce musculoskeletal disorders drugs to treat musculoskeletal disorders such as arthritis, osteoporosis, osteomalacia, and other disorders.This industry includes establishments that produce drugs to treat rheumatoid arthritis, muscle relaxants to reduce muscle pain, and other drugs used in treating osteoarthritis, analgesics drugs, immunosuppressive.

Some of the major drugs in the market include Piroxicam Glaxo, Dolonex, Felden and Piroxicam Pfizer.

The main drug types of musculoskeletal disorders drugs are drugs for rheumatoid arthritis, muscle relaxants and other musculoskeletal disorders drugs.A muscle relaxant is a medication that causes muscle contractions to cease.

The drugs are available in the form of pharmaceutical drugs and biologics.The drugs are administered through oral, parenteral, and others that are classified into branded and generic drugs.

The various mode of purchase includes prescription-based drugs and over-the-counter drugs which are distributed by hospital pharmacies, retail pharmacies/ drug stores and others.

North America was the largest region in the musculoskeletal disorders drugs market in 2021.Middle East is expected to be the fastest growing region in the forecast period.

The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The aging population profile of most countries contributed to the growth of the musculoskeletal disorders drugs market.The increase in patient pool due to rising geriatric population globally, contributed significantly to the growth of the market during the historic period.

According to the WHO, by 2030, one in every six people on the planet will be 60 or older. The proportion of the population aged 60 and up will rise from 1 billion in 2020 to 2.1 billion by 2050. This rise in the geriatric population increased the demand for medical care and drove the healthcare expenditure. This has led to increased demand for pharmaceuticals products, significantly impacting market growth during this period.

Regulatory changes are likely to lead to increased costs relating to new product development and service offerings to clients.These changes are related to data protection such as the European Union’s General Data Protection Regulation (GDPR), changes to drug approval procedures and other regulatory changes.

For instance, according to a study on 100 Data Privacy and Data Security statistics for 2020, GDPR compliance is a top priority for 58% of European companies.The GDPR regulation is a EU law on data protection and privacy of individuals residing the European Union and the European Economic Area (EEA).

It also regulates data anonymization thus maintaining integrity of data dealing with patients and other clinical trial studies. The potential loss of revenue due to delays in product release and additional costs incurred due to stringent approval processes puts strain to investments relating to new product development, thereby affecting the growth of the musculoskeletal disorders drugs market.

Going forward, the market for muscle relaxants is expected to increase with the rise in combination therapy.Combination therapy involves use of more than one medication or drug to treat a disease.

These combinational therapies reduce the frequency of drug administration. For instance, in May 2019, Galt Pharmaceuticals has submitted a Supplemental Abbreviated New Drug Application to the U.S. Food and Drug Administration for Orphengesic Forte an oral formulation of aspirin, caffeine, and orphenadrine for the treatment of pain caused due to musculoskeletal disorders.

The countries covered in the musculoskeletal disorders drugs market report are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela and Vietnam.

Read the full report:

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.


The U.S. FDA refused to grant Emergency Use Authorization for COVID-19 vaccine Covaxin in immunizing kids.
Ocugen's stock price plunged Friday after the Food and Drug Administration declined to issue an emergency use authorization for the Malvern biopharmaceutical company's Covid-19 vaccine. In November, Ocugen (NASDAQ: OCGN) filed an application seeking the emergency use authorization for Covaxin to prevent Covid-19 in children ages 2 to 18. Covaxin is a Covid vaccine developed by Bharat Biotech of India.
Patrick Bafuma is bullish on Legend Biotech (NASDAQ: LEGN) and thinks it might be worth $55 billion by 2027. George Budwell believes his pick, Heron Therapeutics (NASDAQ: HRTX), could jump 1,000% in that time frame. Patrick Bafuma (Legend Biotech): Lost amid the recent market doldrums has been some incredible news.
The race to develop a new gene therapy with CRISPR took some interesting turns recently. On the same day that Intellia Therapeutics (NASDAQ: NTLA) dazzled the medical community with clinical trial results for its lead candidate, the fight for intellectual property rights related to all its candidates took a sharp turn for the worse. Do solid clinical trial results make Intellia a good stock to buy now?
The daily On-Balance-Volume (OBV) line has been in a decline from the middle of January telling us that sellers of LRCX are more aggressive. This difference between the price action and the indicator is a bullish divergence and it is an imprecise forecaster of a possible trading low. The OBV line is down from its January peak.
(Bloomberg) — The chorus is growing from America’s oil executives for President Joe Biden to throw the federal government’s weight behind an industry he once deliberately shunned: U.S. shale.Most Read from BloombergRussian Forces Occupy Site of Nuclear Plant as Fire ContainedUkraine Update: Russian Troops Occupy Nuclear Plant SiteUkraine Update: Russia Blocks Facebook as Media Crackdown WidensRussia’s Rating Cut to Junk; Talks on Tap: Ukraine UpdateWall Street Is Pouncing on Russia’s Cheap Corp
Wheat futures are on track for their biggest weekly rise since at least 1959 as Russia's invasion of Ukraine shuts off a major source of exports of the crucial grain.
The fighting in Ukraine has shut down small but important suppliers to the car industry, closing plants far from the conflict zone, while sanctions and severed trade routes are hindering car and parts shipments to and from Russia, once seen as a growth market.
Shell PLC has snapped up a cargo of Russian crude at a bargain price, ending a [self-imposed embargo on Russian oil by the international energy industry]( Shell bought 100,000 metric tons of Russia’s flagship Urals crude on Friday, according to people familiar with the transaction. It paid $28.50 a barrel below the price of international benchmark Brent crude, the widest discount on record. Lon
An electric vehicle maker considered – and then rejected – North Carolina for a 7,500-job manufacturing plant. It likely came down to politics.
With officials in Germany approving Tesla's $5.5 billion gigafactory in Berlin, founder and CEO Elon Musk is easing his opposition to unionization in the carmaker's California factory.
The main airline ETF has slumped 16% since Feb. 14. Its biggest holdings are Delta Air, United, Southwest and American.
A new study found that baricitinib, a rheumatoid arthritis drug developed by Eli Lilly & Co. and Incyte Corp. , reduced the risk of death among patients who have been hospitalized with severe COVID-19. The new
(Bloomberg) — The Biden administration is weighing a ban on U.S. imports of Russian crude oil as Congress races toward passing such a restriction to punish the Kremlin for its invasion of Ukraine.Most Read from BloombergRussian Forces Occupy Site of Nuclear Plant as Fire ContainedUkraine Update: Russian Troops Occupy Nuclear Plant SiteUkraine Update: Zelenskiy Slams ‘Weak’ NATO, Russia Blocks MediaWhite House Weighs Ban on Russian Oil Imports as Congress FumesPutin’s Financial Isolation by Worl
Palladium prices have climbed to their highest level on record as global sanctions on Russia threaten to disrupt the flow of output from one of the world’s largest producers of the metal.
China summoned some key rare earths companies amid continuously-rising product prices and urged them to ensure a steady supply chain to help cool prices, the regulator said on Friday. The Ministry of Industry and Information Technology said in a statement that it had instructed producers including China Rare Earth Group, China Northern Rare Earth Group and Shenghe Resources to regulate their operation and trading, and to prevent any market speculation or hoarding. The authority also urged the companies to take a lead in promoting a pricing mechanism for rare earths products and jointly bring prices back to a reasonable range, it said.
Gas prices are hitting $5 per gallon in places like San Francisco due to Russia's attack on Ukraine. Sanctions could result in a ban on Russian oil.
There is a sobering new study about the long-term effects of alcohol on your brain; Bradley Blackburn reports for CBS2.
The parent company of Evendale-based GE Aviation is pausing support to Russia amid that country's ongoing invasion of Ukraine.
So says a veteran petro market pro, who spies a bubble about to burst. How to use options to protect your position.


Add a Comment

Your email address will not be published. Required fields are marked *